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limits due to different health care systems and practice patterns.
Health care contacts were reported at a range of 10€ or less to
260€ depending on the type of provider. For diagnostic inter-
ventions similar costs were observed across the countries, except
for more complex procedures. The cost of an urodynamic test
was within the range of 70–175€ other than in Denmark (13€)
and Spain (260€). For countries with DRG systems variability in
unit costs of surgical procedures for UI appears low. In non-DRG
systems procedure costs (including length of stay in surgical
wards) are comparable to DRGs. CONCLUSIONS: Unit costs
for UI treatment vary between the differing healthcare settings
within Europe. The standardized collection of unit cost data in
PURE is the prerequisite for determining UI-related costs of care
in this multinational setting.
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OBJECTIVE: Hyperphosphataemia in patients with end-stage
renal disease can affect mineral homeostasis, resulting in sec-
ondary hyperparathyroidism, osteodystrophy and vascular cal-
ciﬁcation. Several phosphate binders are currently available;
however, they are associated with a range of side effects. Lan-
thanum carbonate is a new phosphate binder that effectively con-
trols serum phosphorus levels. METHODS: We assessed the cost
effectiveness of lanthanum carbonate as a second-line treatment
for patients inadequately controlled using maximum doses of
calcium-based phosphate binders as recommended by the
National Kidney Foundation (USA). Quality-adjusted life years
(QALYs) gained were used as the measure of effectiveness, and
the standard for cost per QALY gained adopted as the threshold
for cost effectiveness was that of the National Institute for Clin-
ical Excellence (NICE) in the UK. The clinical pathways model
used to estimate cost effectiveness had the following structure:
1) Patients who failed on calcium carbonate received a trial
period on lanthanum carbonate; 2) Those who succeeded on lan-
thanum carbonate continued to receive it; 3) Those who failed
on lanthanum carbonate switched back to calcium carbonate; 4)
Serum phosphorus levels were estimated for each subgroup using
clinical trial results; 5) Implied relative risk of mortality (based
on Block et al) was applied to USRDS survival data and thus
QALYs gained were calculated; and 6) Treatment costs were
attached to each pathway. RESULTS: The results demonstrate
that lanthanum carbonate is cost effective at conventional NICE
thresholds for patients whose phosphorus level remains above
6.6mg/dL (2.1mmol/L) when treated with calcium carbonate.
CONCLUSION: For patients who achieve a phosphorus level
below 6.6mg/dL on calcium carbonate, lanthanum carbonate is
unlikely to be cost effective on reasonable assumptions about its
price. Lanthanum carbonate becomes progressively more cost
effective with increasing phosphorus levels for patients treated
with calcium carbonate.
